Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| DePuy Synthes | INDUSTRY |
Not provided
Not provided
Not provided
The objective of this study is to perform a prospective, randomized, controlled clinical trial to compare radiographic fusion rates and patient reported outcomes, including pain and function preoperatively and postoperatively, using Depuy ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft in conjunction with an approved Depuy Synthes pedicle screw system compared to autograft mixed with cortical/cancellous allograft in conjunction with the same DePuy Synthes pedicle screw system used for a one or two - level posterolateral lumbar fusion.
This is a prospective randomized, non-blinded, controlled study. Patients with a diagnosis of degenerative disc disease and/or up to grade I spondylolisthesis and planning to undergo a one or two-level instrumented posterolateral lumbar fusion surgery between L1-S1 will be screened. If eligible and the subject meets all the inclusion criteria and none of the exclusion criteria, the subject will be approached about study participation by the surgeon. If the subject agrees to participate, the consent process will be initiated by the study coordinator. Once the patient has been consented; data including medical history, neurological exam, patient questionnaires (visual analogue pain score (VAS), Oswestry low-back disability questionnaire (ODI), short form health survey (SF-36)) will be collected. Randomization will occur once a surgery date has been scheduled so the appropriate instrumentation can be boarded accordingly. A randomization envelope will reveal randomization treatment group. The envelopes will be generated in a 1:1 fashion and be randomly allocated to an assigned study identification number.
Subjects will be randomized to either: 1) treatment arm where the investigator will use an FDA approved/cleared DePuy Synthes spinal pedicle screw system with ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft or the 2) control arm where the investigator use the same DePuy Synthes spinal pedicle screw system with local autologous bone graft mixed with cortical/cancellous allograft. Both treatment groups represent standard of care lumbar fusion surgeries using two types of bone graft options to create the arthrodesis as comparators.
Once the lumbar fusion surgery has taken place as planned; data will be collected regarding the surgery performed, including operative time, amount of bone graft used, spinal system used, length of hospital stay, and adverse events/complications.
Study subjects will be followed up at 6-weeks, 3-months, 6-months, and 12-months postoperatively at the private practice or clinic. During these routine (standard of care) postoperative visits, subjects will complete questionnaires (VAS, ODI, SF-36, patient satisfaction) and have neurological exam (lumbar spine exam, see appendix 1) completed by the investigator. Adverse events related to device and/or procedure will be evaluated as each postoperative visit. Anteroposterior (AP) and lateral x-rays will be performed at all visits with flexion and extension x-rays added at baseline, 3-months, 6-months, and 12-months. A CT scan of the lumbar spine will be performed during the 12-month postoperative time frame at the Beaumont-Royal Oak Imaging Center. Radiographic analysis will be performed and evaluated for fusion status as evidenced by bony bridging, presence of radiolucency, and development of pseudoarthrosis at each follow-up visit.
This study design reflects the current standard of care for lumbar spinal stenosis, degenerative disc disease and lumbar degenerative spondylolisthesis. Lumbar fusion surgery using pedicle screw fixation with autograft and allograft bone grafting options is treatment of choice after conservative (non-surgical) therapies have been implemented and failed.
Addendum:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle Screw System | Active Comparator | 20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system |
|
| Local Bone Autograft with DePuy Synthes Spinal Pedicle Screw System | Placebo Comparator | 20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system | Combination Product | ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.10 and will be used with the FDA approved DePuy Synthes Spinal pedicle screw system for fusion. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Successful Lumbar Fusion Measured Radiographically | Count of participants with successful lumbar bone fusion as measured by CT scan and flexion/extension x-rays at 12-months as evidenced by the following three criteria: bony bridging, no presence of radiolucency and no development of pseudoarthrosis at the treated lumbar level | 12 months postoperative |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analog Scale for Pain | Number of participants achieving equal to or greater than a 2-point decrease in patient reported outcomes as measured by Visual Analog Scale for pain (0-10 point scale, 0 = no pain and 10 = severe amount of pain) from baseline to 12-months, representing a decrease in pain. | 12 months postoperative |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jad G Khalil, MD | Corewell Health East | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| William Beaumont Hospital | Royal Oak | Michigan | 48073 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 12205416 | Background | Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976). 2002 Aug 15;27(16 Suppl 1):S26-31. doi: 10.1097/00007632-200208151-00007. | |
| 19540168 | Background | Kim DH, Rhim R, Li L, Martha J, Swaim BH, Banco RJ, Jenis LG, Tromanhauser SG. Prospective study of iliac crest bone graft harvest site pain and morbidity. Spine J. 2009 Nov;9(11):886-92. doi: 10.1016/j.spinee.2009.05.006. Epub 2009 Jun 18. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
2 patients were consented but screen failure prior to randomization, leaving 44 patients at start of study
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ViviGen® Cellular Bone Matrix With DePuy Synthes Spinal Pedicle Screw System | 20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system: ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 18, 2019 |
Not provided
Subjects will be randomized to either: 1) treatment arm where the investigator will use an FDA approved/cleared DePuy Synthes spinal pedicle screw system with ViviGen® Cellular Bone Matrix mixed with cortical/cancellous allograft or the 2) control arm where the investigator use the same DePuy Synthes spinal pedicle screw system with local autologous bone graft mixed with cortical/cancellous allograft. Randomization is 1:1
Not provided
Not provided
Participants will be blinded to the randomization group and which bone graft is used during surgery
|
|
| Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system | Combination Product | Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion. |
|
|
| Change in Oswestry Disability Index for Pain and Function |
Number of participants achieving equal to or greater than 15-point decrease in patient reported outcomes as measured by Oswestry Disability Index (0-100 point scale, 0 = least amount of disability, 100 = most severe disability) from baseline to 12-months. |
| 12 months postoperative |
| Change in Short Form Health Survey-36 for Quality of Life: Physical Component Summary | Number of participants achieving equal to or greater than 15-point increase in patient reported quality-of-live outcomes as measured by a composite Physical Component Summary score on the SF-36 (0-100 point scale, 0 = low favorable health state and 100 = most favorable health state) from baseline to 12-months. This Physical Component Summary score is calculated by averaging scores from the Pain, Physical Functioning, Physical Role Limitation, and General Health Perception subscales for each patient at 12 months and at baseline, and calculating a difference. A positive number indicates an increase in physical health, and a negative number indicates a decrease in physical health. | 12 months postoperative |
| Neurological Deficit Per Lumbar Spine Neurological Exam | Count of participants with new or worsening neurological (lumbar motor and sensory) deficit as evaluated by lumbar spine neurological exam from baseline through 12 months. | 12 months postoperative |
| Count of Participants With Revision Surgery by Month 12 | Count of participants with revision surgery by month 12 | 12 months postoperative |
| Count of Participants Developing Pseudoarthrosis by Month 12 | Count of participants developing pseudoarthrosis by month 12 | 12 months postoperative |
| 12038843 | Background | Betz RR. Limitations of autograft and allograft: new synthetic solutions. Orthopedics. 2002 May;25(5 Suppl):s561-70. doi: 10.3928/0147-7447-20020502-04. |
| 10790647 | Background | Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to Autogenous Bone Graft: Efficacy and Indications. J Am Acad Orthop Surg. 1995 Jan;3(1):1-8. doi: 10.5435/00124635-199501000-00001. |
| 14753795 | Background | DeCoster TA, Gehlert RJ, Mikola EA, Pirela-Cruz MA. Management of posttraumatic segmental bone defects. J Am Acad Orthop Surg. 2004 Jan-Feb;12(1):28-38. doi: 10.5435/00124635-200401000-00005. |
| Background | DePuy Synthes. https://www.depuysynthes.com/hcp/spine/products/qs/vivigen-cellular-bone-matrix. Copyright DePuy Synthes 2014-2017. DePuy Synthes Biomaterials Division 1302 Wrights Lane East, West Chester, Pennsylvania 19380. |
| 17672157 | Background | Vaccaro AR, Stubbs HA, Block JE. Demineralized bone matrix composite grafting for posterolateral spinal fusion. Orthopedics. 2007 Jul;30(7):567-70. doi: 10.3928/01477447-20070701-06. |
| 22076647 | Background | Kang J, An H, Hilibrand A, Yoon ST, Kavanagh E, Boden S. Grafton and local bone have comparable outcomes to iliac crest bone in instrumented single-level lumbar fusions. Spine (Phila Pa 1976). 2012 May 20;37(12):1083-91. doi: 10.1097/BRS.0b013e31823ed817. |
| FG001 | Local Bone Autograft With DePuy Synthes Spinal Pedicle Screw System | 20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system. Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system: Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ViviGen® Cellular Bone Matrix With DePuy Synthes Spinal Pedicle Screw System | 20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system: ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. |
| BG001 | Local Bone Autograft With DePuy Synthes Spinal Pedicle Screw System | 20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system. Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system: Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence of Successful Lumbar Fusion Measured Radiographically | Count of participants with successful lumbar bone fusion as measured by CT scan and flexion/extension x-rays at 12-months as evidenced by the following three criteria: bony bridging, no presence of radiolucency and no development of pseudoarthrosis at the treated lumbar level | Posted | Count of Participants | Participants | 12 months postoperative |
|
|
| ||||||||||||||||||||||||||||||
| Secondary | Visual Analog Scale for Pain | Number of participants achieving equal to or greater than a 2-point decrease in patient reported outcomes as measured by Visual Analog Scale for pain (0-10 point scale, 0 = no pain and 10 = severe amount of pain) from baseline to 12-months, representing a decrease in pain. | 4 subjects in autograft arm and 3 subjects in the ViviGen arm did not have 12 month data. | Posted | Count of Participants | Participants | 12 months postoperative |
| |||||||||||||||||||||||||||||||
| Secondary | Change in Oswestry Disability Index for Pain and Function | Number of participants achieving equal to or greater than 15-point decrease in patient reported outcomes as measured by Oswestry Disability Index (0-100 point scale, 0 = least amount of disability, 100 = most severe disability) from baseline to 12-months. | 3 participants in the ViviGen group and 4 participants in the Autograft group did not have 12 month data collected | Posted | Count of Participants | Participants | 12 months postoperative |
| |||||||||||||||||||||||||||||||
| Secondary | Change in Short Form Health Survey-36 for Quality of Life: Physical Component Summary | Number of participants achieving equal to or greater than 15-point increase in patient reported quality-of-live outcomes as measured by a composite Physical Component Summary score on the SF-36 (0-100 point scale, 0 = low favorable health state and 100 = most favorable health state) from baseline to 12-months. This Physical Component Summary score is calculated by averaging scores from the Pain, Physical Functioning, Physical Role Limitation, and General Health Perception subscales for each patient at 12 months and at baseline, and calculating a difference. A positive number indicates an increase in physical health, and a negative number indicates a decrease in physical health. | 4 participants in the ViviGen group and 4 participants in the Autograft group did not complete12 month SF-36 data | Posted | Count of Participants | Participants | 12 months postoperative |
| |||||||||||||||||||||||||||||||
| Secondary | Neurological Deficit Per Lumbar Spine Neurological Exam | Count of participants with new or worsening neurological (lumbar motor and sensory) deficit as evaluated by lumbar spine neurological exam from baseline through 12 months. | 7 participants in the ViviGen Cellular Bone Matrix arm did not complete the 12 month postoperative visit and no data was collected. 5 participants in the local bone autograft arm did not complete the 12 month postoperative visit and no data was collected. | Posted | Count of Participants | Participants | 12 months postoperative |
| |||||||||||||||||||||||||||||||
| Secondary | Count of Participants With Revision Surgery by Month 12 | Count of participants with revision surgery by month 12 | Posted | Count of Participants | Participants | 12 months postoperative |
|
| |||||||||||||||||||||||||||||||
| Secondary | Count of Participants Developing Pseudoarthrosis by Month 12 | Count of participants developing pseudoarthrosis by month 12 | Posted | Count of Participants | Participants | 12 months postoperative |
|
|
12 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ViviGen® Cellular Bone Matrix With DePuy Synthes Spinal Pedicle Screw System | 20 subjects undergoing one or two-level instrumented posterolateral lumbar fusion surgery using ViviGen Cellular Bone Matrix mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system ViviGen® Cellular Bone Matrix with DePuy Synthes Spinal Pedicle screw system: ViviGen® is manufactured by LifeNet Health. ViviGen® Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. | 0 | 19 | 1 | 19 | 9 | 19 |
| EG001 | Local Bone Autograft With DePuy Synthes Spinal Pedicle Screw System | 20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system. Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system: Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion. | 0 | 17 | 0 | 17 | 11 | 17 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac vessel occlusion | Cardiac disorders | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Sacroiliac joint pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Pseuroarthrosis L4-5 | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Hip pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Knee pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Synovial Cyst | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Dural Tear, intraoperative | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| neurogenic claudication | Nervous system disorders | Systematic Assessment |
| ||
| cervical radiculopathy | Nervous system disorders | Systematic Assessment |
| ||
| Lower extremity numbness/weakness | Nervous system disorders | Systematic Assessment |
| ||
| Lower extremity pain | Nervous system disorders | Systematic Assessment |
| ||
| Lower extremity radiculopathy | Nervous system disorders | Systematic Assessment |
| ||
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| COVID-19 infection | Infections and infestations | Systematic Assessment |
| ||
| Surgical site infection | Infections and infestations | Systematic Assessment |
| ||
| Gastroparesis | Gastrointestinal disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jad Khalil, MD | William Beaumont Hospitals | (248) 663-1900 | jad.khalil@corewellhealth.org |
| May 14, 2025 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D013168 | Spondylolisthesis |
| D055959 | Intervertebral Disc Degeneration |
| D011843 | Radiculopathy |
| D013130 | Spinal Stenosis |
| C535531 | Intervertebral disc disease |
| ID | Term |
|---|---|
| D013169 | Spondylolysis |
| D055009 | Spondylosis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
20 subjects undergoing open, one or two-level posterolateral lumbar fusion surgery using local autograft mixed with cortical/cancellous allograft and DePuy Synthes pedicle screw system. Local Bone Autologous Bone Graft with DePuy Synthes Spinal pedicle screw system: Patient's own bone harvested during spinal surgery will be used with the FDA approved DePuy Synthes spinal pedicle screw system to create the fusion. |
|
|
|
|
| Counts |
|---|
| Participants |
|
|
| Counts |
|---|
| Participants |
|
|